Skip to content

AR Training in Adults With Unilateral Amblyopia

Dichoptic Augmented Reality (AR) Training Versus Patching in Adults With Unilateral Amblyopia

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06704737
Enrollment
48
Registered
2024-11-26
Start date
2023-02-25
Completion date
2024-12-20
Last updated
2024-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amblyopia Functional, Amblyopia Unilateral

Keywords

Adult, Augmented reality training, Patching, Neural deficit

Brief summary

This is a single-center, non-randomized controlled trial to compare the effectiveness of binocular AR training with patching for the treatment of adults with unilateral amblyopia. Specific Aim 1 (Primary): To compare the improvement of visual acuity in the amblyopic eye between AR training and patching for the treatment of adults with unilateral amblyopia. Specific Aim 2 (Secondary): To compare the changes of visual functions and pathway selective neural activity in the early visual and cortex subcortical nuclei including the lateral geniculate nucleus between AR training and patching for the treatment of adults with unilateral amblyopia.

Detailed description

Patching the fellow eye (FE) is typically the first line of amblyopia therapy. Patching treatment has been thought to be effective only when started before the age of eight and might bring limited benifits for adults who have decreased visual cortex plasticity (Bhola et al., 2006). However, recent animal and human studies have demonstrated that visual cortex plasticity and visual functions can be enhanced later in life (Kind et al., 2002; Pineles et al., 2020), paving the way for new strategies for amblyopia treatment. Dichoptic/binocular digital therapy has been developed with hope to improve visual functions in amblyopia post the critical period. However, no widely accepted binocular treatments with superiority to patching is available in adults with unilateral amblyopia (Pineles et al., 2020; Oscar et al., 2023). Here, we designed an innovative binocular therapy using augmented reality (AR) training, based on neural deficits in amblyopia, in order to achieve better outcomes. Selective deficits were found in the parvocellular pathway (P pathway) compared to the magnocellular pathway (M pathway) in the monocular processing of visual information in the amblyopic eye (AE) (Wen et al., 2021). In addition to monocular deficits, imbalanced binocular suppression may also play important roles in the visual deficits of amblyopia as suggested by clinical evidence (DeSantis, 2014; Von Noorden, 1996) and psychophysical studies (Baker et al., 2008; Holopigian et al., 1988; Li et al., 2011; Zhou et al., 2013). Based on the neural deficits in unilateral amblyopia, we first apply the push-pull approach (Xu, He & Ooi, 2010; Ooi et al., 2013), which was aimed to reduce sensory eye dominance in previous literatures, into the rebalance of functions of M and P pathways in the AE and the rebalance of binocular interaction, to improve the high spatial detail perception of the AE in daily life under binocular viewing condition, as well as binocular functions. Using AR technique combined with dichoptic device, images are processed differently and dichopticaly presented to each eye of the patients in real time, same in the content but different in contrast, spatial frequency, temporal frequency, and signal-to-noise ratio, allowing them to interact with the surrounding environment in real time during the visual training. We aim to achieve push-pull in monocular M-P pathways in the AE and interocular P-P pathways in the FE and the AE, in order to selectively improve the function of the P pathway in the AE under binocular viewing condition. The proposed trial will be conducted in one study sites in China. For the AR training group, patients need to perform AR training for 2 hours per day at home. For the patching group, patients need to patch the FE for 2 hours per day at home.

Interventions

Dichoptic augmented reality training with dual-pathway (parvocellular pathway and magnocellular pathway) and interocular push-pull paradigms developed based on neural deficits in adults with unilateral amblyopia

DEVICEPatching

Conventional patching therapy.

Sponsors

Eye & ENT Hospital of Fudan University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

1. Aged 18-50 years (including 18 years and 50 years); 2. Best-corrected visual acuity worse than 20/30 but no worse than 20/200 in the amblyopic eye, interocular difference of 2 or more lines, with the better eye within the normal range; 3. Patients with deprivation amblyopia should have relieved the deprivation factors such as opacification of the ocular media (e.g. cataract, nonclearing vitreous opacity, corneal opacities) or other occlusion of the visual axis (e.g. blepharoptosis). 4. Normal binocular alignment including strabismic amblyopia with orthotropia after optical refractive correction or surgical correction, or intermittent exotropia within a range of -15 to 0 prism diopters measured by the prism cover test. 5. Patients should have been applyng optical refractive correction for more than 3 months before enrollment.

Exclusion criteria

1. Organic eye diseases preventing the establishment of good vision (e.g. ptosis, media opacity, nystagmus, paracentral fixation, acute inflammation like keratitis, optic nerve diseases like glaucoma, retinal diseases); 2. Lesions of the brain preventing the establishment of good vision (e.g. cortical visual impairment); 3. A history of ocular surgery (except strabismus surgery) affecting vision (e.g. retinal detachment repair); 4. A history of ocular trauma affecting vision; 5. Receiving amblyopia therapy (except wearing refractive correction glasses) within 2 weeks before enrollment; 6. History of epilepsy or mental illness, or cognitive defects; 7. Currently taking medications or needing to take medications during the study period that may affect vision; 8. Contraindications to magnetic resonance imaging such as implantable electronic device, metal implants (e.g. metal dentures, craniofacial titanium plates), claustrophobia and pregnancy.

Design outcomes

Primary

MeasureTime frameDescription
Change in visual acuity at far1 week, 1month, 3month, 6monthBest-corrected visual acuity in the amblyopic eye measured at the distance of 2.5 meters using standardized logMAR visual charts.

Secondary

MeasureTime frameDescription
Change in visual acuity at near1 week, 1month, 3month, 6monthBest-corrected visual acuity in the amblyopic eye measured at the distance of 2.2 meters using the Freiburg Visual Acuity test.
Change in visual acuity with single tumbling E1 week, 1month, 3month, 6monthBest-corrected uncrowded and crowded visual acuity in the amblyopic eye measured at the distance of 30 centimeters.
Change in contrast sensitivity1 week, 1month, 3month, 6monthContrast sensitivity in each eye measured with forced-choice test under binocular viewing.
Change in faxation stability1 week, 1month, 3month, 6monthFixation stability in each eye measured with EyeLink 1000.
Change in binocular phase combination1 week, 1month, 3month, 6monthBinocular integration measured with phase combination test .
Change in binocular rivalry ratio1 week, 1month, 3month, 6monthBinocular rivalry ratio measured with binocular rivalty test
Change in stereopsis1 week, 1month, 3month, 6monthNear stereopsis measured with Titmus Fly Stereotest pattern.
Change in neural activity corresponding to visual inputs in SSVEP1 week, 1month, 3month, 6monthPathway-selective neural activity in the early visual cortex revealed by SSVEP.
Change in neural activity corresponding to visual inputs in fMRI1 week, 1month, 3month, 6monthPathway-selective neural activity in the early visual cortex and subcortical nuclei including lateral geniculate nucleus revealed by fMRI.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026